Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 3

1(33.3%)

3Total

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07475468Not Yet Recruiting

CP382 - Intermittent Catheter (IC) PRO Panel Plan

Role: collaborator

NCT05843916Phase 3Completed

Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease

Role: collaborator

NCT07377682Recruiting

Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

Role: collaborator

NCT05904938Not ApplicableUnknown

Oral Administration of Actitan-F in Paediatric Diarrhoea

Role: collaborator

NCT05016024Not ApplicableCompleted

Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.

Role: collaborator

All 5 trials loaded